Overview

  • Product nameAnti-CYP4V2 antibody
    See all CYP4V2 primary antibodies
  • Description
    Rabbit polyclonal to CYP4V2
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Rabbit, Horse, Chicken, Guinea pig, Cow, Cat, Dog
  • Immunogen

    Synthetic peptide from a region within internal sequence amino acids 432-481 (YFPNPEEFQP ERFFPENAQG RHPYAYVPFS AGPRNCIGQK FAVMEEKTIL) of Human CYP4V2 (NP_997235)

  • Positive control
    • Jurkat cell lysate

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab90271 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 61 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.

Target

  • FunctionCatalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. The substrate specificity is higher for myristate > laurate > palmitate (C14>C16>C12). May have a role in fatty acid and steroid metabolism in the eye.
  • Tissue specificityBroadly expressed. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, retina, retinal pigment epithelium (RPE) and lymphocytes.
  • Involvement in diseaseBietti crystalline corneoretinal dystrophy (BCD) [MIM:210370]: An autosomal recessive ocular disease characterized by retinal degeneration and marginal corneal dystrophy. Typical features include multiple glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual field. Most patients have similar crystals at the corneoscleral limbus. Patients develop decreased vision, nyctalopia, and paracentral scotomata between the 2nd and 4th decade of life. Later, they develop peripheral visual field loss and marked visual impairment, usually progressing to legal blindness by the 5th or 6th decade of life. Note=The disease is caused by mutations affecting the gene represented in this entry.
  • Sequence similaritiesBelongs to the cytochrome P450 family.
  • Cellular localizationEndoplasmic reticulum membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • BCD antibody
    • CP4V2_HUMAN antibody
    • CYP4AH1 antibody
    • CYP4V 2 antibody
    • CYP4V2 antibody
    • Cytochrome P450 4V2 antibody
    • Cytochrome P450, family 4, subfamily V, polypeptide 2 antibody
    • Retina CYP4V2 antibody
    see all

Anti-CYP4V2 antibody images

  • Anti-CYP4V2 antibody (ab90271) at 1 µg/ml + Jurkat cell lysate at 10 µg

    Secondary
    HRP conjugated anti-Rabbit IgG at 1/50000 dilution

    Predicted band size : 61 kDa
    Observed band size : 61 kDa
    Additional bands at : 40 kDa. We are unsure as to the identity of these extra bands.

References for Anti-CYP4V2 antibody (ab90271)

ab90271 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab90271.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"